Resumen de A new shot against hepatitis C.
The article discusses a clinical trial of an RNA drug that targets microRNA-122 (miRNA-122), called miravirsen, by Harry L.A. Janssen and colleagues at Canada's Toronto General Research Institute. Topics include the prevalence of hepatitis C infection and its role in liver cancer and liver-related diseases, the drugs used to treat hepatitis C, such as interferon and ribavirin, and their side effects, and how targeting miRNA-122 in liver cells disables the hepatitis C virus.
